ERK and p38: two phosphates, and the antibody is the assay

Most phospho-specific antibodies report a modification that correlates with a functional state. For ERK1/2 and p38 the relationship is tighter. These kinases are catalytically inert until two residues in their activation loop are both phosphorylated, and the rate enhancement that follows spans roughly five orders of magnitude. Detect the dual phosphorylation and you have not inferred activity — you have measured it.

Three tiers, and why the architecture exists

The mitogen-activated protein kinase modules are built the same way across eukaryotes: a MAP3K phosphorylates a MAP2K, which phosphorylates a MAPK. ERK1 and ERK2 were cloned and named in the early 1990s as extracellular signal-regulated kinases activated by growth factors, whose activation correlated with tyrosine phosphorylation but also required additional modification ¹.

The three-layer arrangement is not simple redundancy. Huang and Ferrell solved the cascade's rate equations numerically and predicted that the terminal MAPK would behave like a highly cooperative enzyme even though no individual step was assumed to be cooperative. Measurements in Xenopus oocyte extracts confirmed it: the stimulus/response curve was as steep as a cooperative enzyme with a Hill coefficient of 4 to 5, in excess of hemoglobin. The consequence is a switch — the cell moves between two discrete states rather than grading its response, which is what a cascade mediating mitogenesis or cell-fate induction needs ².

Specificity comes from elsewhere. ERK1/2 are proline-directed kinases preferring substrates with a Pro-Xxx-Ser/Thr-Pro sequence, and most substrates additionally carry a D-docking site, an F-docking site, or both. Layered on top, scaffold proteins — KSR1/2, IQGAP1, MP1, and β-arrestin1/2 among them — assemble particular cascade components in particular places, while tyrosine-specific, serine/threonine-specific, and dual-specificity phosphatases make the process reversible ³. ERK1/2 alone phosphorylate hundreds of substrates governing proliferation, survival, growth, metabolism, migration, and differentiation ⁴.

The activation loop is the signal

In 1991 Payne and colleagues digested ³²P-labeled pp42/MAP kinase with trypsin and found a single phosphopeptide by two-dimensional mapping. That one peptide contained both phosphotyrosine and phosphothreonine, and mass spectrometry placed the two sites one residue apart ⁵. That Thr-X-Tyr motif is the defining feature of the family, and the reason a single antibody can report both events at once.

What the dual phosphorylation does to catalysis was quantified a decade later. Prowse and Lew measured the individual reaction steps of ERK2 and found that dual phosphorylation raises overall catalytic efficiency about 600,000-fold and turnover about 50,000-fold, most of it from a roughly 60,000-fold acceleration of phosphoryl transfer itself rather than from tighter substrate binding ⁶. An unphosphorylated ERK2 molecule in a lysate is, for practical purposes, not an enzyme. p38 works the same way, through dual phosphorylation on Thr180 and Tyr182 ⁷.

This is why the phospho-antibody is the assay rather than a surrogate for one — and why the two residues must be considered together. An antibody detecting the threonine alone, or the tyrosine alone, reports a partially modified intermediate, not an active kinase.

The ERK1/ERK2 numbering problem

Here is a genuine and very common source of confusion in figure legends. ERK1 (MAPK3, the p44 band) and ERK2 (MAPK1, the p42 band) carry the same Thr-X-Tyr motif, but the residues sit at different positions in the two sequences. MEK1/2 phosphorylate human ERK1/2 at Tyr204 and Tyr187 respectively, then at Thr202 and Thr185 ³. The identical chemical event is therefore written Thr202/Tyr204 when the author has ERK1 in mind and Thr185/Tyr187 when the author has ERK2 in mind.

Most commercial reagents in this class are raised against the ERK1 sequence around the motif and detect both isoforms, which is why the same antibody is variously sold and cited as "phospho-ERK1/2," "phospho-p44/42 MAPK," and "phospho-MAPK (Thr202/Tyr204)." A reader who sees Thr202/Tyr204 in one paper and Thr185/Tyr187 in the next is looking at the same reagent class and the same biology, not two assays. Rat and mouse sequences shift the numbers again. State the numbering convention and the species in the methods, and treat a two-band pattern at roughly 44 and 42 kDa as the expected result, not as nonspecific binding.

The field has form on this. The BRAF substitution that defines most melanoma was originally reported as V599E ²⁰; the identical substitution is now universally written V600E ³. Residue numbers are conventions attached to reference sequences, and conventions change.

ERK: input, destination, and duration

The canonical input is Ras-Raf-MEK-ERK, engaged by receptor tyrosine kinases and growth factors ³⁴. The critical downstream step is spatial. Brunet and colleagues sequestered p42/p44 MAPK in the cytoplasm using a catalytically inactive MAP kinase phosphatase. Activation was unaffected and cytoplasmic substrates including p90RSK1 were still phosphorylated — but Elk1-dependent transcription and growth-factor-induced re-entry into DNA replication were strongly inhibited ⁸. Getting phosphorylated is not sufficient; the activated kinase has to reach the nucleus.

Once there, ERK and p38 converge on shared machinery. MSK1 is activated in vitro by either ERK2 or p38, sits in the nucleus, and phosphorylates CREB at Ser133 with a Km far below that of PKA, p90RSK, or MK2 ¹⁰ — the same CREB phosphorylation event that appears elsewhere in this series as the convergence point of the cAMP and calcium pathways.

Duration carries information independently of amplitude. In PC12 cells, nerve growth factor raised MAPKK activity more than twenty-fold within five minutes and held it for at least ninety, whereas epidermal growth factor produced a comparable peak at two minutes that returned to baseline by sixty to ninety minutes. Only the sustained NGF signal produced striking nuclear translocation of MAP kinase ¹¹. Same kinase, same magnitude, different outcome, decided by how long the signal lasts. A single-timepoint western blot cannot see this.

p38: stress in, cytokines out

p38 was cloned in 1994 as a protein tyrosine-phosphorylated in response to bacterial lipopolysaccharide. Its sequence at and around the critical phosphorylation sites resembled the yeast HOG1 product, and both proteins were tyrosine phosphorylated after a change in extracellular osmolarity ¹². In the same year, pyridinyl-imidazole compounds that blocked interleukin-1 and tumor necrosis factor production from stimulated human monocytes were shown to act on a pair of closely related MAP kinase homologues, with binding affinity correlating with cytokine inhibition ¹³. p38 arrived already attached to a drug program.

Upstream, activated MKK3 and MKK6 selectively increase p38 activity and drive reporter-gene expression through ATF2 and Elk-1 ⁹. The family has four members — p38α, β, γ, and δ — about 60% identical in sequence but differing in expression pattern, substrate specificity, and sensitivity to inhibitors such as SB203580 ¹⁴. Most phospho-p38 (Thr180/Tyr182) reagents detect more than one family member; which ones matter depends on the tissue.

Downstream, the most consequential substrate is MK2. Mice lacking MK2 survive LPS-induced endotoxic shock and produce roughly 90% less TNF-α, with no change in TNF receptor signaling and no reduction in TNF-α mRNA level or stability — the control is post-transcriptional ¹⁵. That is the basis for two decades of interest in p38 inhibitors for inflammatory disease.

In the nervous system

ERK's role in plasticity was established by pharmacology. PD 098059 blocked MAPK activation in response to NMDA receptor stimulation and to LTP-inducing stimuli and markedly attenuated LTP induction, while having no effect on already-established LTP ¹⁶. The behavioral counterpart followed: hippocampal MAPK activation increased after contextual fear conditioning, and inhibiting MEK blocked the learning ¹⁷.

p38 runs the other direction at the same synapses, mediating induction of metabotropic glutamate receptor-dependent long-term depression at CA3-CA1 — two parallel MAPK cascades supporting opposing forms of plasticity in one circuit ¹⁸. p38 is also the microglial stress kinase. After spinal nerve ligation, activated p38 in the spinal cord is restricted entirely to microglia, colocalizing with OX-42 and not with neuronal or astrocytic markers, appearing within a day and persisting beyond three weeks; intrathecal SB203580 reduces the resulting mechanical allodynia ¹⁹.

Clinical stakes, and why pharma measures phospho-ERK

BRAF is mutated in 66% of malignant melanomas, with a single substitution accounting for about 80% of those ²⁰. In the phase 1 trial of the RAF inhibitor PLX4032, paired tumor biopsies taken before and after two weeks of treatment were assayed for ERK phosphorylation. At the original formulation, substantial inhibition was seen without tumor regression; at the higher exposures achieved with a reformulation, greater than 80% inhibition of ERK phosphorylation in patient tumors correlated with clinical response, alongside an 81% response rate at 960 mg twice daily ²¹. Phospho-ERK immunohistochemistry is a standard pharmacodynamic endpoint in oncology for that reason: it is the most direct measure of whether the drug reached and blocked the pathway in the tissue.

The p38 story has been harder. Inhibitors have been through many trials in inflammatory disease; in chronic obstructive pulmonary disease, a systematic review concludes that efficacy has been limited and clinical results mixed, with combination approaches now the more promising direction ²².

Working with these reagents

These are the antibodies most likely to be picked up by someone new to phospho-work, so the basics are worth stating plainly.

Lysis. Phosphatase inhibitors covering both serine/threonine and tyrosine phosphatases go into the buffer before the buffer touches the sample. Lyse fast, on ice, and do not leave plates at room temperature between aspiration and lysis. Handling itself can change measured phosphorylation: in mouse brain, freeze/thawing samples after homogenization on ice dramatically increased AMPK Thr172 phosphorylation relative to microwave-inactivated controls, reflecting no biological change ²³. The same logic applies to any activation-loop epitope.

Normalization. A phospho-ERK band means nothing alone. Report it as a ratio to total ERK on the same blot, a stripped and reprobed blot, or a parallel lane from the same lysate. A phospho signal that tracks total protein is a change in abundance, not activation.

Baseline. Serum-starve before stimulating. Without a low, defined baseline there is no dynamic range.

Controls. For ERK, EGF or phorbol ester. For p38, anisomycin, sorbitol or another osmotic challenge, or LPS in responsive cells — the stimuli through which the kinase was first characterized ⁷¹². Negative controls are equally cheap: SB203580 for p38 ¹³¹⁴, a MEK inhibitor for ERK ¹⁶. A lambda-phosphatase-treated parallel sample remains the most direct specificity control for any phospho-antibody.

Caveat — High basal phospho-ERK is usually a handling artifact, not biology. ERK responds to a medium change, to a plate being moved, to a temperature shift. A "stimulated" sample showing strong phospho-ERK may be reporting the two minutes it spent on the bench rather than the ligand that was added. Handle the unstimulated control exactly as the stimulated one — same medium change, same time out of the incubator, same pipetting — or the comparison is meaningless. The second half of the caveat is chemical: dual phosphorylation is required for activity ⁵⁶⁷. An antibody detecting only the threonine or only the tyrosine does not report an active kinase, and its signal should not be described as "activated ERK" or "activated p38."

Choosing and reporting the reagent

The five-pillar framework from the International Working Group for Antibody Validation — genetic, orthogonal, independent-antibody, tagged-protein, and immunocapture/mass-spectrometry strategies, applied in an application-specific way — is the reference standard ²⁴. For this reagent class the orthogonal pillar is unusually accessible: stimulate, inhibit, and dephosphorylate, and show the signal moves as predicted in all three directions. Report catalog number, lot, host species, the numbering convention and species used, the phosphatase inhibitors in the lysis buffer, and the loading control.

Phospho-specific antibodies of this type are typically used for western blot, immunofluorescence, and immunohistochemistry, and are conventionally run alongside a total-protein antibody against the same target.

Catalog no.	Antibody	Host
P46101	Phospho-ERK/MAPK (Thr202/Tyr204)	Rabbit
P46201	Phospho-p38 MAPK (Thr180/Tyr182)	Rabbit

References

1. Boulton TG, Nye SH, Robbins DJ, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 1991;65:663–675. doi:10.1016/0092-8674(91)90098-j · PMID 2032290
2. Huang CY, Ferrell JE. Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 1996;93:10078–10083. doi:10.1073/pnas.93.19.10078 · PMID 8816754
3. Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res. 2012;66:105–143. doi:10.1016/j.phrs.2012.04.005 · PMID 22569528
4. Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607–632. doi:10.1038/s41580-020-0255-7 · PMID 32576977
5. Payne DM, Rossomando AJ, Martino P, et al. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J. 1991;10:885–892. doi:10.1002/j.1460-2075.1991.tb08021.x · PMID 1849075
6. Prowse CN, Lew J. Mechanism of activation of ERK2 by dual phosphorylation. J Biol Chem. 2001;276:99–103. doi:10.1074/jbc.M008137200 · PMID 11016942
7. Raingeaud J, Gupta S, Rogers JS, et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem. 1995;270:7420–7426. doi:10.1074/jbc.270.13.7420 · PMID 7535770
8. Brunet A, Roux D, Lenormand P, et al. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 1999;18:664–674. doi:10.1093/emboj/18.3.664 · PMID 9927426
9. Raingeaud J, Whitmarsh AJ, Barrett T, Dérijard B, Davis RJ. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol. 1996;16:1247–1255. doi:10.1128/MCB.16.3.1247 · PMID 8622669
10. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 1998;17:4426–4441. doi:10.1093/emboj/17.15.4426 · PMID 9687510
11. Traverse S, Gomez N, Paterson H, Marshall C, Cohen P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J. 1992;288:351–355. doi:10.1042/bj2880351 · PMID 1334404
12. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 1994;265:808–811. doi:10.1126/science.7914033 · PMID 7914033
13. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739–746. doi:10.1038/372739a0 · PMID 7997261
14. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007;1773:1358–1375. doi:10.1016/j.bbamcr.2007.03.010 · PMID 17481747
15. Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol. 1999;1:94–97. doi:10.1038/10061 · PMID 10559880
16. English JD, Sweatt JD. A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. J Biol Chem. 1997;272:19103–19106. doi:10.1074/jbc.272.31.19103 · PMID 9235897
17. Atkins CM, Selcher JC, Petraitis JJ, Trzaskos JM, Sweatt JD. The MAPK cascade is required for mammalian associative learning. Nat Neurosci. 1998;1:602–609. doi:10.1038/2836 · PMID 10196568
18. Bolshakov VY, Carboni L, Cobb MH, Siegelbaum SA, Belardetti F. Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3-CA1 synapses. Nat Neurosci. 2000;3:1107–1112. doi:10.1038/80624 · PMID 11036267
19. Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci. 2003;23:4017–4022. doi:10.1523/JNEUROSCI.23-10-04017.2003 · PMID 12764087
20. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954. doi:10.1038/nature00766 · PMID 12068308
21. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467:596–599. doi:10.1038/nature09454 · PMID 20823850
22. Ahmadi A, Ahrari S, Salimian J, et al. p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics. Cell Commun Signal. 2023;21:314. doi:10.1186/s12964-023-01337-4 · PMID 37919729
23. Scharf MT, Mackiewicz M, Naidoo N, O'Callaghan JP, Pack AI. AMP-activated protein kinase phosphorylation in brain is dependent on method of killing and tissue preparation. J Neurochem. 2007;105:833–841. doi:10.1111/j.1471-4159.2007.05182.x · PMID 18088373
24. Uhlen M, Bandrowski A, Carr S, et al. A proposal for validation of antibodies. Nat Methods. 2016;13:823–827. doi:10.1038/nmeth.3995 · PMID 27595404

Sourcing note. Primary literature located through PubMed; every quantitative figure was taken from the source article’s own record. Findings are reported at the grain of the study that produced them and those grains are not interchangeable. Product specifications are from the current Pel-Freez datasheets.